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Androgen receptor (AR) has been shown to play a key role in mediating the 
transcriptional regulatory network directing prostate cancer initiation, 
development and progression. To gain insights into the AR-dependent 
transcriptional regulatory network, we utilized the ChIP-Seq approach and 
generated genome-wide binding maps of AR in the LNCaP prostate cancer cell 
line. From our bioinformatic analyses of AR binding sites (ARBS), we found an 
enrichment of motifs belonging to the NFI family. We demonstrated that a 
member of the NFI family, NFIC, shown to be over-expressed in clinical prostate 
tumors, overlaps with a large fraction of ARBS across the genome. Our analysis 
revealed that the recruitment of NFIC was independent of androgen treatment, 
indicating NFIC as a potential pioneer factor. In addition, we showed that NFIC 
was required for the global modulation of AR-dependent target genes including 
KLK2, KLK3, and TMPRSS2. Interestingly, we found another well characterized 
AR pioneering factor, FoxA1, to be recruited to the ARBS associated with these 
genes. However, the expressions of these genes were FoxA1 independent, 
suggesting NFIC was the more important pioneering factor at these ARBS. We 
hypothesized that NFIC and FoxA1 could co-pioneer AR and went on to 
demonstrate that NFIC and FoxA1 played distinct roles globally for different 
classes of AR modulated genes and their associated ARBS. Collectively, our 
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study suggests NFIC is a novel pioneering factor that is complementary to FoxA1 
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CHAPTER 1 INTRODUCTION 
 
1.1 Prostate development and prostate cancer 
The prostate belongs to the male reproductive system and is an accessory gland 
slightly larger than the size of a walnut. The prostate gland functions as secreting 
prostatic fluid that usually constitutes more than half of the volume of the semen.  
Prostate development is dependent upon the integration of steroid hormone 
stimulations. A multitude of genes and signaling pathways has been shown to 
regulate single or multiple steps prostate development, which includes epithelial 
budding, the elongation of the duct, branching morphogenesis, and cellular 
differentiation (Powers and Marker, 2013). Almost all prostatic acini developed 
by outgrowths from the urethral epithelium and develop and grow into the 
mesenchyme tissues in adjacent areas. The prostatic glandular epithelium 
differentiates from the endodermal cells, while the associated mesenchyme of the 
prostate differentiates into the dense stroma and the prostatic smooth muscle. In 
the development of male reproductive systems, the prostate gland composed of 
several glandular and non-glandular components are usually developed by the 9th 
week of embryonic growth, formed by the condensation of mesenchyme, urethra 
and Wolffian ducts. 
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The disorder of the prostate gland consists of Prostatitis, Benign prostatic 
hyperplasia and finally leads to prostate cancer (Figure 1.1). 
Prostatitis is defined as inflammation of the prostate gland. This sort of prostatic 
disorder mainly comprises of four different forms, namesly acute prostatitis , 
chronic bacterial prostatitis, chronic non-bacterial prostatitis, and Category IV 
prostatitis that is relatively uncommon in the general population, also classified as 
a type of leukocytosis. Each type of prostatitis has different causes and outcomes.  
Benign prostatic hyperplasia (BPH) happens when the prostate enlarges and 
results in difficulty in urination. BPH often occurs in older men. The cause of 
BPH is not well established, but potential factors that may contribute to BPH 
include DHT. DHT is thought to play a potential role in the development in BPH, 
by inducing cell growth in the prostate. Older men who stops producing DHT are 
observed not to develop BPH(Isaacs and Coffey, 1989). 
Prostate cancer is one of the most common types of cancers affecting aged men in 
developed countries and has been considered the second leading cause of cancer 
related death in US males. The most common form of prostate cancer is 
adenocarcinoma. At the beginning cancer growth is only limited in the interior of 
the prostate, and at certain stage the prostate cancer cells may progress to a more 
advanced state, by metastasizing from the prostate and invade into other various 
organs of the body, especially the bones and lymph nodes (Coffey and Pienta, 







Figure 1.1 H&E stain of micrograph showing prostate gland disorders 
The H&E stain graph of prostatitis on the top panel and prostate adenocarcinoma on 




1.2 Androgen and Androgen receptor  
Testosterone is a steroid hormone primarily derived from the testis. It plays key 
physiological roles ranging from development of male reproductive tissues such 
as prostate and epididymis (Desjardins, 1978; Cunha et al., 1987) to the 
acquisition or promotion of the secondary male sexual characteristics during 
puberty (Mooradian et al., 1987). Apart from the male-associated phenotypes, 
androgens also regulate development or functions of other tissues and organs, for 
instance, the bone and muscle tissues (Finkelstein et al., 1987), hair follicles on 
the skin (Messenger, 1993), sebaceous gland (Deplewski and Rosenfield, 2000), 
and adipose tissues (Schroeder et al., 2004). 
The androgenic effect in a wide array of tissues is usually carried out by androgen 
after it’s metabolized into 5-dihydrotestosterone (DHT) (Randall, 1994), which is 
a more potent form of androgen. In the majority of androgen targeted tissues, 
DHT binds to androgen receptor to form a regulatory complex to regulate target 
genes, thus maintaining proper function of these vital organs (Liao and Fang, 
1969). Androgen receptor plays a vital role both in the development of normal 
prostate gland and prostate carcinoma, and is expressed throughout prostate 
cancer progression and it remains expressed in many prostate tumors resistant to 
androgen ablation therapy (Agoulnik and Weigel, 2008). Functional AR is 
expressed through different stages of prostate carcinogenesis, including PIN and 
early carcinoma, advanced carcinoma, and eventually in metastatic carcinoma. 
Androgens are found to regulate the proliferation of epithelial cells, leading to the 
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adenocarcinoma, therefore androgens that modulate AR activity may result in 
uncontrolled cell proliferation in the form of cancer.  
 
1.3 AR structure and its mode of action in prostate cancer 
The AR is also known as NR3C4 (nuclear receptor subfamily 3, group C, member 
4). It is a nuclear transcription factor and is most closely related to the 
progesterone receptor (Raudrant and Rabe, 2003). Androgen receptor carries out 
its function as a DNA binding transcription factor by regulating gene expressions 
(Mooradian et al., 1987).  
The genomic structure of AR has been highly conserved throughout mammalian 
evolution. The AR gene is located on the X-chromosome at position Xq11-12. It 
spans around 90 kb and contains eight exons that code for nearly more than 900 
amino acids within a 10.6 kb mRNA. Two isoforms of AR has been identified. 
The less predominant isoform A is 87 kDa with its N-terminus truncated resulting 
from in vitro proteolysis, while predominant isoform B is full length with 110 
kDa mass (Wilson and McPhaul, 1994). Similar to many other steroid receptors, 
the AR is modular in structure and consists of distinct functional domains known 
as the amino-terminal domain transactivation domain (NTD), DNA binding 
domain (DBD), carboxyl terminal ligand-binding domain (LBD) (Brinkmann et 
al., 1989; Tsai and O'Malley, 1994). The DBD and LBD are connected by a hinge 
region (Figure 1.2).  
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LBD, DBD and the N-terminal of the hinge segment are highly conserved during 
evolution, while the NTD sequence is mostly variable. The NTD consists of 
homopolymeric repeats including polyglutamine and polyglycine and contains the 
major transactivation domain which is termed as activation function (AF)-1 
responsible for transcriptional activity once it is bound by ligand. It also contains 
activation function 5 (AF-5) that is responsible for the activity without ligand 
binding. The LBD has specific motifs for ligand binding, as well as activation 
function-2 (AF-2) domain responsible for agonist induced activity. AF-2 in AR 
mainly binds preferably to N-terminal FXXFL motif but not FXXFL motifs that 
are mostly found in many coactivators (He et al., 2002; He and Wilson, 2003). 
Furthermore, the LBD contribute to not only the tethering to heat shock proteins 
(HSPs), but also AR homo- and hetero-dimerization. The DBD consists of two 
zinc-finger motifs. The DNA recognition specificity is determined by the first 
zinc finger of the DBD, and the second zinc finger of DBD is mainly responsible 
for the stabilization of the DNA and AR complex, as well as AR dimerization. In 









Figure 1.2 Schematic diagram featuring structural domains of the two 
isoforms (AR-A and AR-B) of the human androgen receptor.  
The numbers above the two structural isoforms indicates the number of amino 
acid residues separating the domains starting from the N-terminus on the left to C-
terminus on the right.  AR contains three functional domains, namely NTD (exon 
A/B), DBD (exon C), and LBD (exon E to F). NTD and LBD are mainly 
responsible for AR transcriptional activities, and LBD have additional functions 
such as associating AR to HSPs and dimerization with DBD. DBD is required for 





AR mode of action in mediating transcriptional regulation in prostate cancer in 
highly ligand induced. In the absence of androgen stimulation, AR exists in the 
cytoplasm as a complex with the HSPs as chaperones (Figure 1.3). Once bound 
by ligand such as DHT converted from testosterone, AR undergoes 
conformational change that triggers the subsequent dissociation of itself from 
HSPs. This turns on the subsequent phosphorylation and homodimerization of AR, 
leading to the translocation of dimerized AR into the nuleus where a serial of 
events occurs.  After AR moves into the nuleus, it recognizes and docks itself to 
the canonical ARE (Chang et al., 1995; Gelmann, 2002; Harris et al., 2009).  The 
binding of AR to the ARE will subsequently facilitate the AR complex to recruit 
other interacting proteins to mediate the downstream transcriptional regulation. 
These recruited proteins include general transcriptional machinery such as RNA 
PoII, chromatin remodeling complexes and transcriptional coactivators and 





Figure 1.3 AR mode of action in prostate cancer 
After testosterone released from plasma proteins is converted to DHT by 5-
reductatse, AR becomes bound by DHT and HSP is dissociated caused by DHT 
binding, leading to AR dimerization. The dimerized AR subsequently translocated 
into the nucleus and binds to ARE, which facilitates recruitment of co-activators 





1.4 AR interacting proteins in AR mediated transcription 
AR plays a central role in the transcriptional regulation in prostate cancer, but it 
does not function alone. The androgen regulation in prostate cancer cell lines 
often involves the formation of diverse AR transcriptional complexes, and this 
regulatory network mainly consists of components of the general transcriptional 
machinery, AR coactivators and corepressors, and specific transcription factors 
(Shang et al., 2002; Heemers and Tindall, 2007).  
AR may regulate its downstream transcription by regulating both transcriptional 
initiation and elongation. General transcription factors to enhance AR 
transcription involve the formation of preinitiation complex (PIC) to promote the 
recruitment of RNA PoII to the AR target gene promoters. Besides the direct 
contact of AR with general transcription factors, AR has been shown to interact 
with RNA PoII  directly by the subunit RPB2 (Lee et al., 2003).  
Up to now a huge number of nuclear receptor coregulators of AR have been 
identified. They can be broadly classified as AR coactivators and corepressors, 
but they can also be classified based on the particular cellular activities they have 
to regulate transcription. These cellular activities may include components of the 
chromatin remodeling complex were shown to alter DNA topology and associated 
with loss of canonical nucleosomal ladder. For instance, the switching / sucrose 
nonfermenting (SWI/SNF) complex were shown to stimulate AR activity in an 
ATP dependent manner (Marshall et al., 2003). Histone modifiers affect AR 
transcriptional activity by modifying histone residues by acetylation, methylation, 
phosphorylation, ubiquitination, and glycosylation. Such modifications would 
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result in changes of the net charge of the nucleosome and thereby changes in the 
conformation of the histone. For example, histone acetylase (HAT) are commonly 
asscociated with transcriptional activation while the histone deacetylase (HDAC) 
recruitment render a more compact chromatin structure and transcriptional 
repression (Xu and O'Malley, 2002). Histone methylation, however, can render 
both transcriptional activation and repression depending on the position of the 
histone residues modified. For instance, H3K4 methylation is associated with 
active genes, while H3K9 and H3K27 methylation often indicate repressed state 
of genes (Mellor, 2006). Histone demethylase such as lysine specific demethylase 
1 (LSD1) and JMJ domain-containing family of histone demethylases (JMJD1A 
and JMJD2C) have recently drew attention to their role in demethylating mono, di 
and trimethylated H3K9, resulting in activation of AR dependent transcription 
(Metzger et al., 2005; Yamane et al., 2006; Wissmann et al., 2007). And 
Coactivator-associated arginine methyltransferase (CARM-1) is one of the well 
studied histone methyltransferases (HMTs) to interact with SRC coactivators and 
is classified as a secondary coactivator (Chen et al., 1999). 
 
1.5 Decoding AR cistromes in prostate cancer cells 
Early studies on transcriptional regulation by AR were largely gene and site 
specific, with limited number of candidates (Cleutjens et al., 1996). However, AR 
signaling involves hundreds of targets genes and the regulation by AR appears to 
have high differential expression kinetics as well based on time course expression 
profiling (Tan et al., 2012). Therefore the development of techniques such as 
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Chromatin Immunoprecipitation coupled with microarray (ChIP-chip) and 
Chromatin Immunoprecipitation coupled with massively parallel sequencing 
(ChIP-seq) has provided much more comprehensive insights into the studies of 
genome wide AR cistromes and transcriptional activities. By combining ChIP-on 
chip data with gene expression profile, transcription factors such as FoxA1, Oct1 
and GATA2 have been identified as AR collaborators that control androgen-
mediated transcription (Wang et al., 2007). For instance, FoxA1 is a well studied 
pioneering factor of AR in prostate cancer (Gao et al., 2003), and its role in 
defining distinct classes of AR binding programs has recently been discovered 
(Sahu et al., 2011; Wang et al., 2011). The general model for the AR 
transcriptional complex is illustrated in Figure 1.4. I would like to elaborate on 





Figure 1.4 Model of AR coregulatory network  
Pioneering factors such as FoxA1 and GATA2 preoccupy chromatin to modulate 
chromatin structures prior to hormone stimulation. Upon DHT stimulation, AR is 
recruited to distal enhancers and further recruits a hierarchical assembly of co-
activator complexes including p160, Oct1, HATs and HMTs, general transcription 
machinery, PoII to ARE to start downstream transcription.  
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1.6 Well Characterized AR collaborative factors 
AR-mediated transcription is composed of a wide array of coordinated events, 
such as chromatin stucture remodeling, epigenetic signature modifications, 
chromosomal looping events and polymerase tracking (Wang et al., 2005). AR 
collaborative factors regulate AR transcriptional activities with diverse functions 
on AR and regulating its transcriptional output, therefore are often overexpressed 
and contribute to carcinogenesis in prostate cancer (Heinlein and Chang, 2004).  
 
1.6.1 FoxA1 
FoxA1 is short for Forkhead box protein A1. It is also known as hepatocyte 
nuclear factor 3-alpha (HNF-3α) and is encoded by FOXA1 gene. FoxA1 belongs 
to the FKH family of DNA binding transcription factor and plays key roles in the 
development of various organs including liver, pancreas, breast and prostate (Lee 
et al., 2005).  In the early years it was shown to be involved in the regulation of 
several ER target genes such as TFF-1 (Beck et al., 1999) as well as interacting 
with ERα. Later studies proved that FoxA1 is required for modulating chromatin 
structure, thereby facilitating ERα recruitment to mediate ER transcriptional 
activities and this is the first study to establish FoxA1 as a pioneering factor of 
ERα (Carroll et al., 2005).  Furthermore, FoxA1 was also implicated in prostate 
cancer development and progression by interacting with AR and regulate AR 
target genes (Gao et al., 2003), thus a lot of studies emerged to focus on its role in 
AR mediated transcription (Jia et al., 2008; Lupien et al., 2008). FoxA1 has 
recently been shown to possess a cell type-specific functions which primarily rely 
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on its differential recruitment to chromatin at enhancers, subsequently leads to 
chromatin structure changes and functional interplay with lineage-specific 
collaborative factors. The differential recruitment of FoxA1 in prostate and breast 
cancer is defined by the distribution of mono- and dimethylated H3 lysine 4 
residues. Therefore FoxA1 translates epigenetic signatures into changes in 
chromatin states to establish cell type specific transcriptional programs.   
Most recently, studies have investigated the genome wide redistribution of ARBS 
after depleting FoxA1 in prostate cancer cell lines and discovered that FoxA1 
defines three distinct classes of ARBS, which are lost, conserved or gained after 
its depletion. The AR redistributed binding program is nicely correlated with 
similar patterns in the redistribution of gene expression profiling (Sahu et al., 
2011; Wang et al., 2011) (Figure 1.5). These studies provided a more 
comprehensive global picture on FoxA1 regulation in prostate cancer, that apart 
from FoxA1 pioneered ARBS, there are also ARBS that is independent on FoxA1 
regulation, and thereby eliciting needs for new studies to explore what other 
pioneering factor might come into play to regulate the AR mediated transcription 






Figure 1.5 Diagram showing the model for FoxA1 mediated reprogramming 
of distinct classes of AR enhancers in the LNCaP prostate cancer cells.  
In the lost AR binding program, FoxA1 faciliates AR recruitment to ARE in 
relatively open chromatin regions. Nucleosome remodelling is not induced upon 
AR binding to ARE in this class of enhancers. In the conserved AR program, AR 
recruitment to ARE is independent of FoxA1, and the binding events induce 
nucleosome remodelling. In the third type of program in which AR binding is 
gained after FoxA1 depletion, FoxA1 inhibits AR binding, in spite of the presence 
of strong AREs. In all the above three classes of AR binding programs, eRNAs 




1.6.2 GATA2 and Oct1 
By integrating Chromatin Immunoprecipitation with tiled oligonucleotide 
Microarrays, previous studies have identified transcription factors such as 
GATA2 and Oct1 to be cooperating in mediating AR transcription. They were 
shown to form a regulatory hierarchy with AR to regulate androgen dependent 
gene expression and prostate cancer progression (Wang et al., 2007). 
Even earlier studies have discovered that GATA family members have the ability 
to open compact chromatin structures via zinc finger motifs (Boyes et al., 1998), 
therefore it may also serve the role of pioneering factor that modulate chromatin 
to facilitate AR binding. However, Oct1 is not required for AR recruitment to 
PSA and TMPRSS2, indicating Oct1 functions downstream to GATA2 and 
cooperate to work together with AR. Silencing GATA2 and Oct1 results in a 
significant decrease in the androgen dependent cell proliferation. 
A later study utilized ChIP-microarray technique to map ARBS and histone H3 
acetylation loci in C4-2B prostate cancer cell line, and manage to find large 
portion of ARBS to be marked by AcH3. From the analysis of the ARBS 
sequence motifs, they also discovered FoxA1, GATA2 to be AR coregulators. 
Adopting transient siRNA knockout experiments, they discovered that these 
coregulators of AR have diverse effects on the expression level of several AR 





1.6.3  NKX3.1 
NKX belongs to a subfamily of Homeobox Genes which were shown to be 
aberrantly expressed in cancers. Human NKX3-1 is largely confined within the 
prostate gland (Bieberich et al., 1996). The implication fo NKX3-1 in prostate 
cancer development was addressed in recent studies. NKX homeodomain has 
been observed to be enriched in AR cistrome analysis. NKX3-1 is the first known 
marker for prostate epithelial differentiation. Studies have shown that NKX3-1 
collaborate with AR at several AR target prostate cancer model genes such as 
PSA, TMPRSS2 and FKBP5, and it regulate AR in a feed forward manner (Tan et 
al., 2012). 
Functional analysis has shown that NKX3-1 collaborate with AR and pioneering 
factor such as FoxA1 to promote prostate cancer survival.  
 
1.6.4 ETS family of transcription factors 
The ETS family comprises of several transcription factors containing highly 
conserved ETS DNA binding domain (Karim et al., 1990) . The ETS family of 
transcription factors plays important roles in regulating diverse cellular processes 
such as cell proliferation, cell differentiation, angiogenesis and apoptosis (Sevilla et 
al., 1999). ETS transcription factors could function both as coactivator or corepressor 
depending on the cellular context (Sharrocks et al., 1997; Sharrocks, 2001) . The 
function of this family of transcription factors in cancer was notably found to be 
through gene fusion with another protein and in the context of prostate cancer, 
various papers have reported the discovery of recurrent ETS fusion genes (Tomlins et 
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al., 2008). Among all gene fusions of ETS family members such as ETV1, ETV4 and 
ETV5 occurring in prostate cancer, the most common type of occurring variant of 
ETS gene fusion in prostate cancer is the TMPRSS2-ERG fusion gene (Kumar-Sinha 
et al., 2008) . From AR ChIP-on ChIP studies in prostate cancer cell line, the ETS 
motif was found to be enriched at AR-bound promoter regions, and members such as 
ETV1 and ERG were subsequently found to be collaborative factors of AR (Massie et 
al., 2007). Interestingly, while ETS-1 and ETV1 were found to be AR coactivators in 
a feed forward manner (Shin et al., 2009), ERG, on the other hand, was recently 
implicated to play the role of AR corepressor in androgen dependent transcriptions 
(Sun et al., 2008). 
Genome-wide cistrome studies of AR and ERG in VCaP prostate cancer cells have 
shown that ERG suppresses androgen dependent transcription as well as epithelial 
differentiation (Yu et al., 2010). A recent study has investigated further into the 
mechanism of the transcriptional collaboration between AR and ERG in ERG 
overexpressed prostate cancer cells (Chng et al., 2012). They assigned functional 
roles of various corepressors such as ERG, HDACs and EZH2 in mediating 
metastasis in a way that they cooperate in a coregulatory network centered by AR to 
attain optimal androgen signaling for prostate cancer progression and development.  
 
1.7 Pioneering factors as potential drug targets 
Pioneer factors are an emerging class of transcription factors that contribute to the 
cell-type-specific transcriptional programs and facilitate transcription factors 
binding to enhancers by modulating chromatin accessibility (Zaret and Carroll, 
2011; Jozwik and Carroll, 2012). Pioneering factors are usually prebound to 
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condensed chromatin in a hormone independent manner, and its modulation of the 
chromatin accessibility via various molecular mechanisms, they are able to 
facilitate recruitment of other transcription factors to turn on the subsequent 
transcription. Recent studies on nuclear receptors have identified a variety of 
pioneering factors in different classes of cell lines. Besides the role of FoxA1 as 
pioneering factor of AR in prostate cancer, it has also been shown to pioneer the 
Estrogen Receptor (ER) mediated transcription in breast cancer, by facilitating 
ERα recruitment and modulating chromatin accessibility at the regulatory sites of 
ERα target genes (Carroll et al., 2005; Lupien et al., 2008; Eeckhoute et al., 2009) 
(Figure 1.6).  
PBX1 has been shown to be a novel pioneering factor for the ER-mediated 
transcriptional response that drives aggressive tumors in breast cancer.  PBX1 
translate specific epigenetic signatures into an open chromatin state that guides 
the recruitment of ERα and its regulated transcriptional programs are highly 
associated with poor prognosis in breast cancer patient (Magnani et al., 2011). 
Ap2γ is another novel pioneering factor and it has recently been shown to play a 
role in ERα recruitment and mediating long range chromatin interactions in 
response to estrogen stimulation in breast cancer. It also has interplay with FoxA1 
in mediating ER dependent transcription as well as long range chromatin 
interactions (Tan et al., 2011).  
Another pioneering factor GATA3 has been shown to act upstream of FoxA1 to 
directly affect ER enhancer accessibility in breast cancer cells, and its depletion 
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resulted in a global redistribution of active histone marks such as H3K4me1 and 
H3K27Ac (Theodorou et al., 2013). 
Due to the importance of pioneer factors in mediating transcription in hormone 
dependent cancer, they constitute attractive therapeutic drug targets for cancer 
treatment. Examples such as FOXA1 is found to be play the role as pioneering 
factor to both ERα mediated transcription and tumor growth in breast cancer and 
AR mediated transcription and cancer progression in prostate cancer, therefore the 
development of a specific inhibitor to FOXA1 would provide a useful clinical 
utility for the treatment of ER+ hormone-resistant breast cancer and AR 







Figure 1.6 Cell type specific FoxA1 recruitment recognized by the lineage-
specific H3K4 methylation distributions  
FoxA1 recruitment occurs in a cell-specific manner. The FoxA1 are directed to 
bind to its respective response elements recognized by active enhancers marked 
by lineage specific H3K4me1 and H3K4me2. In contrast, H3K9 methylation 
marks silenced enhancer regions and those repressed loci are usually devoid of 
FoxA1 binding. FoxA1 are found to bind and actively modulate the associated 
chromatin to a more relaxed state, thereby facilitating lineage-specific 
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transcription factor such as ERα, AR or other collaborative factors recruitment to 
the more exposed binding sites in response to hormone stimulation to establish 




1.8 NFI family of transcription factors 
Our study utilized genomic approaches to identify and characterize novel 
collaborative factor of AR. By adopting ChIP-seq technology (Schmidt et al., 
2009), we generated AR binding patterns across the genome in LNCaP prostate 
cancer cells. Apart from the other well characterized AR cofactor motifs such as 
Forkhead, ETS, NKX, GATA, another motif that is highly enriched motifs in the 
AR cistrome belongs to the NFI family of DNA-binding proteins. This family of 
transcription factors consists of four members, namely NFI-A, NFI-B, NFI-C and 
NFI-X (Qian et al., 1995). They are known to function in both viral DNA 
replication and in the regulation of gene expression (Gronostajski, 2000; Perez-
Casellas et al., 2009) (Figure 1.7). 
NFI proteins have modular structures. The N-terminal domains of NFI proteins 
mediate DNA binding and dimerzation, and the C-terminal domains usually 
regulate transcriptional activation and/or repression (Mermod et al., 1989; 
Bandyopadhyay and Gronostajski, 1994). NFI binding sites have been found in 
many mammalian tissues, including brain, liver, lung and mammary gland, 
pituitary, retina and various other tissues (Cereghini et al., 1987; Courtois et al., 
1990; Watson et al., 1991; Furlong et al., 1996; Bachurski et al., 1997; Bedford et 
al., 1998). In most of these tissues, the function of NFI proteins has been indicated 
to be important for gene expressions. The NFI family of transcription factors 
usually binds as a either hetero- or homodimer with a preferred binding sequence 
as a palindrome containing two half sites TTGGCANNTGCCAA on duplex DNA 
(Gronostajski et al., 1985). NFI proteins are found to be either repressing or 
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activating gene expression in a gene specific manner (Furlong et al., 1996; 
Johansson et al., 2003). It has been recently shown to be involved in long rang 
regulation of gene expression by forming chromatin barrier that blocks the 
propagation of heterochromatin structures (Esnault et al., 2009). 
Studies also showed that the NFI proteins have dual role in hormone-mediated 
transactivation of mouse mammary tumor virus (MMTV) promoter. NFI family 
of transcription factors are found to  play a role in both transcriptional activation 
and nucleosome remodeling via the formation and maintenance of a preset 
chromatin structure in the MMTV promoter region in mouse (Chikhirzhina et al., 
2008). 
In situ hybridization assays in mouse indicated that the four NFI gene members 
are expressed in a relatively unique but widely overlapping pattern during 
embryogenesis, suggesting that it’s due to the differential expression of these 
genes that lead to differential expression of the target proteins that regulate 
development (Chaudhry et al., 1997).  
NFI proteins also have implications in cancer from their role in the control of cell 
growth. The aberrant fusion between the C-terminus of NFIB and HMGIC leads 
to pleomorphic adenomas (Geurts et al., 1998). However, the overexpression of 
NFIX has opposing role in cancer development by suppressing oncogenic 
susceptibility in mink lung epithelial cells (Sun et al., 1998). The early findings of 
the role of NFI proteins in DNA replication might be related to the influence of 
the altered expression of NFI proteins on cell proliferation in cancer development. 
The current models for investigating the role of the four members in cancer are 
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mainly systems that are depleted or overexpressing the specific isoforms of NFI 







Figure 1.7 Domains and alternative splicing of vertebrate NFI genes.  
The top figure illustrates the general feature of NFI proteins and the below shows 
the alternatively spliced products of the four NFI genes from vertebrates, NFIA, 
NFIB, NFIC and NFIX. The chromosomal locations of each individual member 
are indicated below the name of the member. NFI proteins are generally 
composed of the N-terminal DNA-binding and dimerization domain and the C-
terminal regions including the proline-rich transactivation domain (Gronostajski, 
2000).   
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1.9 NFIC CCAAT binding transcription factor 
Based on the clinical transcriptome studies available in Oncomine database, we 
narrowed down to NFIC which is overepressed in the metastatic prostate tumor 
samples (Lapointe et al., 2004; Yu et al., 2004).  
Up till now there have been relatively limited studies of NFIC in prostate cancer, 
and most studies on the biological functions of NFIC have been performed on nfic 
knock out mice, which showed that NFIC played an essential role for odontogenic 
cell proliferation and odontoblast differentiation during tooth root development 
(Lee et al., 2009). Nfic-deficient mice exhibited normal molar crown formation 
but aberrant odontoblast differentiation during root formation (Steele-Perkins et 
al., 2003). Mice that lack NFIC develop abnormal roots and lose their teeth, 
which shares similar symptoms to the radicular dentin dysplasia I in humans. 
Studies found significant increases in the several mRNA expressions in NFIC 
depleted cells, suggesting that NFIC might regulate odontoblast cell migration 
and differentiation, and thus play a role in the root development (Kim et al., 2009). 
One study on the transcriptional regulatory function of NFI proteins based on the 
model of NFI-dependent mouse mammary tumor virus (MMTV) promoter 
indicated that the expression of NFIC or NFIX, but not NFIA or NFIB proteins, 
represses glucocorticoid induction of the MMTV promoter in HeLa cells. The 
repressive regulatory functions by NFIC appears to be highly cell type specific 
that such regulation is observed in HeLa and COS-1 cells but not 293 or JEG-3 
cells (Chaudhry et al., 1999).  
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The role of NFIC in cancer development has limited implication up to date. A 
study of ERα centric regulatory network in breast cancer suggest that NFIC 
negatively regulates the cyclin D1 (CCND1) oncogene expression, therefore its 
expression is negatively correlated with breast cancer proliferation (Eeckhoute et 
al., 2006). However, the role of NFIC in the context of AR in prostate cancer has 
not yet been established. 
 
1.10 Aim of the study 
In this study, we integrate molecular and computational approach to decode AR 
and NFIC cistrome in prostate cancer cells. By combining ChIP-sequencing with 
microarray gene expression profiling, we endeavor to find out the role of NFIC in 
AR mediated transcriptional network. We established NFIC as a novel pioneering 
factor of AR and functionally dissect its role as a pioneering factor in relation to 
another pioneering factor, FoxA1, in mediating AR transcriptional regulations. 
We found huge amount of AR and NFIC overlapping cistromes also converge 
FoxA1 binding events, suggesting that FoxA1 comes into play with AR and NFIC 
regulatory network. Lastly, we discovered that NFIC mediates AR transcriptional 
regulation at distinct classes of ARBS defined by their dependency on FoxA1, 
and at these sites NFIC and FoxA1 differentially modulates chromatin 







CHAPTER 2. MATERIALS AND METHODS 
 
2.1 Reagents and antibodies  
The hormone dihydrotestosterone (DHT) was purchased from Tokyo Chemical 
Industry. The antibodies we used for ChIP-assay were purchased from the 
following companies: anti-AR (sc-816 and sc-815x), anti-NFIC (sc-5567), normal 
rabbit IgG (sc-2027), normal goat IgG (sc-75 2028) from Santa Cruz, and anti- 
FoxA1 (ab5089) from Abcam.  
The antibodies used for western blot analysis were shown as follows. Primary 
antibodies used were: anti-AR (AR441) from Labvision, anti-NFIC (sc-5567) 
from Santa Cruz; anti- FoxA1 (ab5089) and anti-βactin (ab3280-500) from 
Abcam. Secondary antibodies used were: donkey anti-goat IgG HRP (sc-2033) 
from Santa Cruz; ECL anti-rabbit IgG horseradish peroxidase (HRP) linked whole 
antibody (NA934V) and ECL anti-mouse IgG HRP linked whole antibody (NA931V) 
from Amersham. 
 
2.2 Cell culture  
LNCaP cells were purchased from American Type Culture Collection (ATCC). 
LNCaP were maintained in RPMI Medium 1640 (RPMI) with 10% fetal bovine 
31 
 
serum (FBS), 1 mM sodium pyruvate, 100 units/ml penicillin and together with 
30 μg/ml gentamycin. LNCaP cells were maintained in hormone deprived phenol 
red free RPMI medium for at least 3 days followed by DHT or ethanol treatment. 
 
2.3 Cryogenic preservation and recovery of cells  
Early passages of LNCaP cells were trypsinized and spun down at 1,000 rpm for 3 
mins to remove the trypsin. Cell pellet was resuspended in culture media which was 
further supplemented with 45% FBS and 5% dimethyl sulfoxide (DMSO) (Sigma), 
and then aliquoted into 2 ml Cryobank Vials (Thermo Scientific, Nunc). The vials 
were placed into a pre-cooled isopropanol-filled container for slow freezing at -80˚C. 
After freezing overnight, the vials were transferred to a liquid nitrogen tank for long 
term storage. During recovery, the cells were thawed quickly at 37˚C and transferred 
to T75 flask for culture. The medium was changed the next day to remove DMSO. 
 
2.4 Western Blot Analysis 
After LNCaP cells were stimulated with DHT for 2 hours,  we use Triton X lysis 
buffer (0.25% Triton X-100, 1mM EDTA, 10 mM TrisHCl, 150 mM NaCl) to 
lyse the cell membrane. Total protein lysates were collected and protein 
concentration was subsequently quantified using Pierce BCA Protein Assay kit 
(Thermoscientific). Then we prepared 20 to 30 ug of protein lysates of each 
sample and mixed them with 5x SDS loading buffer, followed by denaturing at 
99˚C for 5 mins. After that, the protein lysates were resolved on 10% SDS 
polyacrylamide gel (SDS-PAGE) and subsequently transferred onto the 
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nitrocellulose membrane (GE Healthcare). The transferred membrane was 
blocked with 5% milk for 1 hr at room temperature before it was incubated with 
corresponding primary antibodies and secondary antibodies at an optimized duration 
and temperature. For signal detection, ECL plus Western Blotting Detection System 
(Amersham) was sprayed onto the surface of the membrane and subsequently 
incubated in dark for 5 minutes before the membrane was exposed to films.  
 
2.5 RNA Isolation and Real-time Reverse Transcription reaction (RT-qPCR) 
LNCaP cells were pretreated with ETOH or 10 nM DHT for 12 hrs, followed by 
extraction of total cellular RNA using TRI® Reagent (Sigma).  After precipitated 
with 75% ETOH, chloroform was added to facilitate RNA isolation. The 
extracted RNA was then purified using the Invitrogen PureLinkTM RNA Mini 
Kit according to the manufacturer’s protocol. After measuring RNA quality and 
concentration using Nanodrop, 1 μg RNA was obtained to undergo reverse 
transcription using Oligo (dT) primer (Promega), dNTP Mix (Fermentas), 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) (Promega) 
and M-MLV RT 5X Buffer (Promega). After cDNA are synthesized, real-time 
qPCR was subsequently performed by adding the KAPA SYBR FAST qPCR kit. 
CT values were analyzed with the ABI 7900HT Fast Real-Time PCR System to 
obtain relative expression. The sequences for real-time qPCR primers of cDNA 
are listed in Appendix I. The experiments were repeated at least three times to 




2.6  Chromatin Immunoprecipitation assays 
LNCaP cells were treated with 100nM DHT or EtOH for 2 hours before the cells 
were fixed with 1% formaldehyde (Sigma-Aldrich, Missouri). After cell pellets were 
collected, they were subsequently lysed with SDS lysis buffer with cocktail 
Proteinase Inhibitor and underwent sonication to shear the genomic DNA into lengths 
of 500-1000 bp. From the sonicated samples, 30 uL was aliquoted and kept as input. 
The rest of the sheared chromatin was then precleared with normal rabbit/goat IgG 
(Santa Cruz Biotechnology, Santa Cruz) and sepharose beads A or A/G (Zymed, San 
Francisco) for at least 2 hours in 4°C. It’s followed by incubation overnight for 
complete immunoprecipitation after adding the specific antibodies and sepharose 
beads. On the next day, the beads were washed with four rounds of washing buffers 
to remove non-specific bindings. Then the protein bound DNA complex was 
subjected to elution and subsequent reverse-crosslinking at 65°C overnight to 
completely isolate DNA fragment with the protein complex. The DNA was then 
purified with QIAquick spin PCR purification kit (Qiagen, California). Real-time 
quantitative Polymerase Chain Reaction (q-PCR) was carried out by using the KAPA 
SYBR FAST qPCR kit. Amplified DNA products were subsequently detected using 
the ABI 7900HT Fast Real-Time PCR System. The relative binding profile was 
determined by calculating the ratio of immunoprecipitated DNA over the input. 
Real-time qPCR primer sequences for ChIP assays are listed in Supplementary 




2.7 Short interfering RNA (siRNA) studies  
We transfected LNCaP cells with 100 nM siRNA against NFIC, AR, or FoxA1 
purchased from Dharmacon or negative control siRNA from 1stBase via 
Lipofectamine™ RNAiMAX Transfection Reagent (Invitrogen). Cells continued 
to be incubated for 72 hr.  After that, cells were treated with vehicle or 10 nM 
DHT for another 12 hr followed by collected for ChIP, Real-time qPCR and 
western blot analyses.  
 
2.8 ChIP-Sequencing 
After quantification using Pico-green ds DNA assay kit (Invitrogen) , 5ng of 
immunoprecipitated DNA were obtained and used for ChIP-Seq library construction. 
The ChIP-Seq DNA sample Prep Kit (Illumina) was utilized for library preparation 
with some minor modifications. The ChIP DNA was made to undergo end-repair 
followed by adapter ligation. Platinum Pfx DNA polymerase (Invitrogen) was then 
used to amplify the ChIP-DNA. Electrophoresis of the amplified DNA products on a 
2% agarose gel was subsequently performed. Detection of the amplified DNA 
products was done by staining the gel with SYBR® Green I Nucleic Acid Gel Stain 
(Invitrogen). DNA products of size 200-300bp were extracted by gel excision and 
purified. Confirmation of the size and quality of the extracted purified ChIP DNA 
was done using bioanalyzer prior sequencing on the Solexa platform. The sequencing 
depth for each library was at least 10million tags. ChIP-Seq read tags were aligned to 
the reference human genome (UCSC, hg18). The binding peaks were determined 




2.9 Co-immunoprecipitation (Co-IP)  
LNCaP cells were maintained in full serum RPMI medium for the Co-IP 
experiments. After cells were seeded for at least three days, they were 
subsequently trypsinized and lysed to obtain whole cell lysate. This is followed by 
pre-clearing process of the cell lysate with Protein A-Agarose beads (Roche 
Applied Science) at 4°C for 4 h. Before the IP process, we collected an aliquot of 
around 30 ul and kept it at -80°C as input for the final western blot analysis. After 
pre-clearing, we add 5 mg of anti-NFI (H-300, sc-5567) to the supernatant and 
incubated the mixture on the roller overnight at 4°C. The next morning we added 
30ul Roche beads into the incubated mixture and continued incubation for another 
1.5 h at 4°C. After that we washed the mixture with TBS for four times 
consecutively. Finally, we removed supernatant and heated the beads at 99°C for 
5 min followed by elution with SDS loading buffer for the subsequent western 
blot analysis. 
 
2.10  Microarray expression profiling  
Total RNA was extracted and purified from LNCaP cells, under the NC and NFIC 
depleted or FoxA1 depleted conditions. The cells were pre-treated with ETOH or 
10 nM DHT for the 12 hours.  Then the Invitrogen PureLinkTM RNA Mini Kit 
was used according to the manufacturer’s protocol. RNA from three biological 
replicates was then processed to cRNA using the Illumina® TotalPrepTM-96 
RNA Amplification Kit (Ambion) according to the manufacturer’s instructions. 
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Subsequently direct hybridization assay was performed with the HumanRef-8 v2 
Expression BeadChip Kit and scanning the chip array using the BeadArray 
Reader (Illumina). The BeadStudio software was subsequently used to process the 
image data and GeneSpring GX11 software was further implemented to analyze 
the expression data.  
 
2.11 Gene Ontology (GO) Analysis 
GO was performed using the IPA (Ingenuity Pathway Analysis) online software 
on NFIC depleted microarray. NFIC activated and repressed DHT responsive 
genes were analyzed respectively. Threshold for DHT responsiveness is 1.3 fold 










CHAPTER 3. RESULTS 
 
3.1  NFIC as a novel AR collaborative factor 
3.1.1 Identification of NFIC as a potential AR cofactor in LNCaP prostate 
cancer cells 
To gain insight into the AR coregulatory network in mediating androgen 
dependent transcription in prostate cancer and to discover novel AR collaborators 
in prostate cancer, we first performed AR ChIP-Seq in the androgen-dependent 
prostate cancer cell line, LNCaP to obtain a genome wide map of AR binding 
events (Tan et al., 2012). AR ChIP-seq was performed at 2 hour after DHT 
treatment. We managed to obtain 18,117 AR peaks in the ETOH treated condition 
and 75,296 peaks in DHT treated condition based on FDR 0.05.  
Next we used our in house motif discovery algorithm called Center of 
Distribution (CENDIST) to analyze the ARBS sequences. CENTDIST program is 
designed based on an algorithm that scans across the genome wide binding sites 
and rank motifs of transcription factors available in TRANSFAC database 
according to the enrichment of center distribution around the binding events of the 
ChIP-seq dataset (Zhang et al., 2011). By inputting obtained AR peaks into 
CENDIST, we discovered significant enrichment of several transcription factor 
family motifs including Forkhead, ETS, and NKX as previously reported (Figure 
1A). In addition, we also found NFI motif among the top ten most highly enriched 
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motifs derived from this analysis, indicating members of NFI family of 
transcription factors might play a potential role in the AR mediated transcription. 
After examining the Oncomine database that deposit cancer transcriptome studies, 
we found that NFIC, one of the NFI family of transcription factors, to be over-
expressed in metastatic prostate carcinoma with respect to normal prostate tumor 
in several clinical prostate tumor transcriptome studies (Lapointe et al., 2004; Yu 
et al., 2004).  This indicates that NFIC might play a role in prostate cancer 












Figure 3.1 NFI motifs are highly enriched in AR binding peaks 
(A) CentDist motif enrichment analysis of the top co-occupying transcription 
factor family motifs from AR ChIP-seq peaks under the condition of DHT 
stimulation. The motif of families of transcription factors are ranked based on the 
score of the distribution of the top member within the transcription factor family 
respectively. (B) Boxplot comparing the transcript expression level of NFIC in 
prostate adenocarcinoma and metastasis prostate tumor samples based on clinical 
studies available in the Oncomine database of transcriptomes (Yu et al. study). 
The differential gene expression data is centered on the median of expression 





3.1.2 Generation of NFIC binding cistromes in LNCaP prostate cancer cell line 
We next examined the potential role of NFIC as an AR collaborative factor. By 
performing NFIC ChIP-qPCR on known binding sites associated with AR model 
target genes such as KLK3, KLK2, and TMPRSS2, we observed NFIC and AR 
are co-localized at these loci. Based on these findings we would like to expand the 
scope for the NFIC binding events across the genome by performing genome 
wide ChIP sequencing of NFIC in LNCaP prostate cancer cell line under the same 
2 hours hormone stimulation condition as AR ChIP-seq. Adopting FDR less than 
0.05 in the in-house CCAT peak calling algorithm (Xu et al., 2010), we identified 
89,377 and 82,645 NFIC binding sites in LNCaP cells prior to and after DHT 
treatment, respectively. De novo motif analysis of NFIC binding sites was 
subsequently performed and it revealed an enriched binding motif that is highly 













Figure 3.2 Generation of NFIC ChIP-seq library in LNCaP cells 
(A) ChIP-qPCR of AR and NFIC binding profile at the PSA enhancer, KLK2 
enhancer and promoter regions, and two ARBS around TMPRSS2. The data 
represents the mean ± SEM of at least 3 independent assays. (B) Logos showing 
the canonical ARE available from the Transfac database in the top panel and 





3.1.3 NFIC cistromes overlap with AR binding events 
We observed that NFIC shares huge proportion of overlapping binding events 
between DHT and ethanol treated conditions, which in turn also overlaps 
considerably with ARBS (Figure 3.3 A and B).  
The previous ChIP-qPCR of AR and NFIC recruitment on several AR model 
genes can further be visualized on the USCS genome browser from the binding 
peaks of the AR and NFIC ChIP-seq datasets. The co-localization of AR and 
NFIC at PSA enhancer, KLK2 enhancer and promoter, and two sites associated 
with TMPRSS2 can be observed (Figure 3.3 E).  
We also investigated the genomic distribution of AR and NFIC binding events. 
Most of our AR binding sites are located distances away from the transcriptional 
start sites (TSS), while the NFIC binding events occurs both at distal and 
proximal regions relative to the TSS. Interestingly, the AR and NFIC co-localized 
binding sites exhibits similar patterns to most of the AR binding sites, that 
majority of these binding events are found far away from the TSS (Figure 3.3 D). 
This suggested that the collaboration between NFIC and AR most probably 
occurs at enhancers of the genes to modulate downstream transcription. 
To investigate whether NFIC interact with AR endogenously in LNCaP prostate 
cancer cells, Co-immunoprecipitation experiment was subsequently performed. 
Cell lysates were incubated with NFIC antibody and we pulled down the potential 
protein complexes using specifically designed beads. After western blot analysis 
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using AR antibody, we managed to observe a weak interaction between AR and 
NFIC, as compared to the intensity after negative control IgG pull down. This 
provided support that NFIC not only co-localize with AR, but also physically 
interact with AR, possibly by forming a transcriptional complex (Figure 3.3 C). 
However, the Co-IP experiments need to be optimized to obtain a better 





























Figure 3.3 AR and NFIC are co-localized in LNCaP cells 
(A) Venn diagram illustrating the overlap between AR binding peaks under DHT 
treatment and NFIC ChIP-seq peaks in both ETOH and DHT treated conditions. 
(B) Percentage of AR unique, NFIC unique and AR/NFIC shared binding events.  
(C) Co-immunoprecipitation experiments showing the interaction between AR 
and NFIC. (D) Genome-wide distribution of AR and NFIC binding sites with 
respect to the transcription start sites (TSSs) of RefSeq genes. (E) UCSC Genome 
browser (Hg18) featuring representative androgen dependent AR model genes, 
KLK3 (top left panel), KLK2 (top right panel) and TMPRSS2 (bottom panel), co-









3.1.4 NFIC mediates AR transcriptional activity 
To confirm the effect that NFIC had on AR-mediated transcription is at least, in 
part, attributed to NFIC binding on the cis-regulatory elements, we cloned the two 
AR binding sites (C7, C8), that were shown to recruit NFIC in vivo on androgen 
stimulation (Figure 3.4) respectively into a luciferase reporter plasmid. The 
predicted AR and NFIC binding motif of each of the AR binding site was then 
distorted via mutagenesis separately prior to performing reporter assays. 
Androgen-induced reporter activities of both binding sites were decreased when 
the AR or NFIC binding motifs were abolished (Figure 3.4), pointing to the 





Figure 3.4 Ligand dependent response at ARBS requires AR and NFIC 
The top panel is the schematic diagram illustrating the reporter constructs used in the 
transient transfection analysis. The Bottom panel shows the reporter assay after 
LNCaP cells were transfected with reporter constructs. Prior to transfection, LNCaP 
cells were treated with or without DHT for 24 hrs. C7 and C8 ARBS full mutated 
ARE and NFIC motifs were cloned into pGL4-TATA and assessed for their 
luciferase reporter activity. Empty vector pGL4-TATA was integrated as a negative 





3.2 Characterization and Validation of NFIC as pioneering factor to AR  
3.2.1 NFIC binding events at ARBS are independent of androgen stimulation  
We moved on to globally analyze the NFIC binding events. To validate the NFIC 
ChIP-seq datasets, we randomly selected 5 high tag intensity, 5 medium tag 
intensity and 10 low tag intensity NFIC binding sites. The ChIP-qPCR validation 
of these binding events shows the NFIC recruitment happens to be independent of 
DHT treatment for all 20 binding sites tested (Figure 3.5 A).  
The genome wide binding profile of AR and NFIC showed that AR binding is 
minimal prior to DHT treatment in both AR unique and AR and NFIC co-
localized regions, while the occupancy of NFIC at both NFIC unique and AR and 
NFIC overlapping regions is comparable before and after androgen stimulation. 
This indicates the binding of NFIC to its binding sites is independent of androgen 
stimulation.  The scatter plot showing the distribution of the tag intensity of each 
NFIC binding sites available in either ETOH or DHT treated ChIP-seq library 
exhibits a high correlation between the two datasets. This provided additional 
evidence that NFIC binding events are indeed ligand independent (Figure 3.5 B 
and C). 
Together with the substantial overlap between AR and NFIC binding events after 
androgen stimulation, our data suggested that NFIC might play a role as a pioneer 
factor of AR that first binds to ARBS prior to DHT treatment and subsequently 
enhances the transcriptional competency of AR. One of the most well studied 
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pioneer factors to AR in prostate cancer cells is FoxA1, which remodels the 
chromatin accessibility rendering it competent for other transcription factor 
binding (Lupien et al., 2008; Magnani et al., 2011). Hence it would be intriguing 
to explore whether NFIC also possesses the ability of pioneering the 




















Figure 3.5 NFIC genome wide recruitment is ligand independent  
(A) ChIP-qPCR of NFIC occupancy at the 5 high tag intensity binding sites, 5 
medium intensity binding sites and 10 low intensity binding sites randomly 
picked from the NFIC ChIP-seq dataset. The data represents the mean ± SEM of 
at least 3 independent assays.  (B) Comparison between average tag densities of 
binding sites after peak calling using CCAT in both ethanol and DHT treated 
NFIC ChIP-seq binding maps that also have ARBS. (C) Scatter plot showing the 






3.2.2 NFIC and AR do not regulate each other 
To investigate the role of NFIC as pioneering factor to AR, we adopted transient 
siRNA knockdown approach to transfect into the LNCaP cells to examine the 
subsequent effect of NFIC depletion on AR recruitment and androgen dependent 
gene expressions. It would be important to find out whether there’s a mutual 
regulation between AR and NFIC in the first place. After knocking down AR and 
NFIC respectively, we observed that the depletion of NFIC has no appreciable 
effect on AR expression both in mRNA level and protein level, indicating AR is 
not a direct target of NFIC. On the other hand, NFIC expression was unaffected 
by AR knockdown or DHT stimulation, confirming that NFIC is not an AR-













Figure 3.6 NFIC and AR do not regulate each other 
(A and B) Effect of NFIC silencing on AR mRNA expression level. Starved 
LNCaP cells were transfected with either negative control siRNA or siRNA 
agains NFIC, followed by DHT or ETOH treatment for 6 hours. Total RNA was 
then isolated and quantified using real-time RT-qPCR with the primers of AR, 
NFIC and GAPDH genes. Subequently all mRNA expressions were normalized 
against GAPDH expression levels. The data presented are relative expression to 
GAPDH ± SEM of at least 3 independent experiments.  (C) Western blot showing 
the protein levels of AR and NFIC as well as loading control β-actin after 





3.2.3 NFIC mediate AR dependent transcription 
Next, we sought to determine the requirement for NFIC in AR mediated 
transcriptional response. AR and NFIC were observed to be co-localized at 
several AR target genes such as PSA, KLK2, and TMPRSS2. NFIC depletion 
resulted in a significant reduction of the expression of these AR model target 
genes (Figure 3.7 A) as well as the AR recruitment to its binding sites associated 
with these genes (Figure 3.7 B), suggesting that NFIC acts upstream of AR 
recruitment, thereby promoting AR signaling. Above results provide support that 
NFIC plays a role as an AR collaborative factor in regulating AR target gene 
expression 
To obtain more candidate genes regulated by NFIC for further analysis, we 
performed genome wide microarray gene expression analysis under the condition 
of NFIC depletion on LNCaP cells with or without DHT treatment (Fig 3.7 C). 
Our analysis revealed 1868 DHT responsive genes by adopting 1.3 fold change 
cut-off in comparison of the expression profile prior and after DHT treatment. 
Interestingly, the depletion of NFIC affected the expression of a significant 
number of DHT-induced (402) and DHT-repressed genes (158), indicating that 
NFIC plays the role of either a transcriptional coactivator or corepressor to 
mediate AR-mediated transcription. The expression profiling array also provides a 
candidate pool of NFIC target genes in the context of androgen regulation. Taken 
together, our results potentiated the role of NFIC as a pioneer factor of AR that 
acts upstream and subsequently mediates AR transcriptional regulation.  
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To further analyze the genome wide microarray profiling data after NFIC 
silencing, we use IPA gene ontology to investigate the cellular pathways and 
processes involved in NFIC regulation of AR dependent transcription. NFIC 
activated and repressed gene sets were both analyzed by IPA. Cancer related 
cellular process involved in NFIC regulation include cellular movement, cell 
death, cell proliferation and cell development. This further proves that NFIC plays 
























Figure 3.7  NFIC regulates AR dependent genes 
(A) Effect of NFIC silencing on PSA, TMPRSS2, KLK2 mRNA expression 
levels. LNCaP cells were maintained in hormone depleted medium followed by 
transfection with either control negative control siRNA or siRNA targeting 
against NFIC prior to stimulation with or without 10 nM of DHT for 12 hr. Total 
RNA was isolated and amplified with real-time RT-qPCR primers for PSA, 
TMPRSS2 and KLK2. mRNA expression levels were normalized against 
GAPDH. (B) ChIP-qPCR of AR occupancy after NFIC silencing at the PSA, 
KLK2, and TMPRSS2. (C) Microarray gene expression profiling was performed 
on LNCaP cells transfected with control or NFIC siRNA and stimulated with 
ETOH as vehicle or DHT for 12 hours. The heatmap represents all DHT-
regulated genes and fold change in expression is indicated below. All results 
represent the average of 3 independent experiments ±S.E.M. (D). Gene Ontology 
using IPA showing cellular process involved via the regulation of the NFIC 





3.3 FoxA1 form co-regulatory complex with NFIC in Mediating AR 
Transcriptional Regulation 
So as to reveal a more comprehensive mechanism of the AR and NFIC regulatory 
network, we decided to investigate additional potential players. To achieve this, 
we analyzed NFIC cistrome that also contains ARBS via CENTDIST motif 
analysis program to discover motifs that are also centered around AR and NFIC. 
As expected, both NFI and ARE motifs were highly ranked at these binding sites, 
and interestingly, the second highly enriched motif revealed by CENDIST is 
Forkhead motif (Figure 3.8 A). This indicates that NFIC and AR might form a 
transcriptional regulatory network with factors that belong to the Forkhead family. 
Since the role of FoxA1 as a pioneering factor to mediate AR gene transcription 
has been recently studied and reported (Lupien et al., 2008; Serandour et al., 
2011), we would like to investigate the potential role of FoxA1 in the AR and 
NFIC regulatory network. 
Collaborations between multiple pioneer factors to mediate the transcriptional 
competency of regulatory elements have been reported. For instance, FoxA1 has 
been shown to cooperate with AP-  occupied by 
both factors there is a functional interplay between AP-2γ and FoxA1 to mediate 
ER transcription and long range interaction(Tan et al., 2011).To study the 
potential interplay among AR, NFIC and FoxA1, we utilized the FoxA1 ChIP-Seq 
dataset in LNCaP cells from the previous study by our group (Tan et al., 2012). 
Integrating the DHT stimulated AR, NFIC and FoxA1 ChIP-Seq datasets, we 
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discovered a huge proportion of AR and NFIC overlapping binding sites that are 
also bound by FoxA1 (Figure 3.8 B).  
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Table 1 Summary of the unique tag counts and total number of peaks called 





















SCS801 AR DHT 13,252,823 75,296 
CHL005 NFIC ETOH 918,0715 89377 
CHL006 NFIC DHT 994,3604 82645 
CHL001 FOXA1 ETOH 13,462,620 79,975 























Figure 3.8 FoxA1 is a potential interplayer of AR/NFIC network 
(A) CentDist output of the top co- occurring transcription factor family motifs 
from DHT stimulated AR and NFIC overlapping ChIP-seq peaks. (B) Venn 
diagram illustrating the overlap between DHT stimulated AR, NFIC and FoxA1 
ChIP-seq peaks. (C)  Screenshots of AR, NFIC and FoxA1 ChIP-seq peaks 




In agreement with previous studies, by examining the heatmap of genome wide 
FoxA1 binding profile, similar to the binding profile of NFIC, the pattern of 
FoxA1 binding is generally independent of androgen stimulation in our study, and 
the majority of AR and NFIC co-localized sites also contain substantial amount of 
FoxA1 occupancy (Figure 3.9A). Furthermore, by comparing the tag intensity 
distribution of FoxA1 binding peaks on AR unique, NFIC unique and AR/NFIC 
overlapping regions, we found that FoxA1 binding events are more enriched at 
AR and NFIC co-localized regions than AR and NFIC uniquely occupied regions 
(Figure 3.9B). All these results suggested that FoxA1 possibly forms a 












Figure 3.9 FoxA1 binding is highly enriched in AR/NFIC overlapping regions 
(A) Heatmap of AR (red), NFIC (green) and FoxA1 (purple). ChIP-seq tag 
intensity sorted according to NFIC (DHT) tag intensity (top-bottom: highest to 
lowest) and centered on AR (DHT) peaks in a 2 kb window. 1-3: Groups of 
common or unique NFIC binding sites identified, namely (1) AR unique; (2) 







Before depleting FoxA1 for the subsequent analysis, we also noted that silencing 
FoxA1 or NFIC did not affect the expression of the other; neither did it have any 
appreciable effect on AR protein level (Figure 3.10A). Then based on the 
available genome wide ChIP-seq datasets of AR, NFIC and FoxA1, we randomly 
selected ARBS co-localized with FoxA1 only, as well as ARBS that are co-
occupied uniquely by NFIC, and examined the AR recruitment at these sites after 
introducing siRNA against NFIC and FoxA1 respectively. Not surprisingly, AR 
recruitment was regulated by FoxA1 at ARBS void of NFIC occupancy, while 
NFIC regulated AR recruitment at sites bound by only NFIC itself (Figure 3.10B).  
FAIRE-qPCR was subsequently performed to investigate the role of NFIC and 
FoxA1 on modeling chromatin openness in different classes of ARBS that could 
contribute to AR recruitment and subsequent transcription. Under normal 
conditions a relatively high FAIRE signal detected by qPCR suggests that the 
chromatin state at specific loci is relatively open in state. From the FAIRE qPCR 
results, it has been revealed that at NFIC unique ARBS, FAIRE signal is 
compromised upon NFIC depletion, but not after FoxA1 knockdown, while for 
FoxA1 unique ARBS it is FoxA1 that modulates chromatin state instead of NFIC 






















Figure 3.10 NFIC and FoxA1 pioneer AR recruitment at NFIC unique and 
FoxA1 unique ARBS respectively 
(A) Western blot showing the effect of NFIC, FoxA1 silencing on AR, NFIC and 
FoxA1 as well as loading control β-actin protein levels. (B) ChIP-qPCR of AR 
occupancy after FoxA1 silencing at the PSA, KLK2, and TMPRSS2. (C) 
Heatmap showing the AR ChIP-qPCR experiment after NFIC or FoxA1 silencing 
on randomly selected NFIC unique ARBS and FoxA1 unique ARBS. The 
intensity of the relative enrichment of % input is indicated below. All relative 
enrichments of individual ARBS have been normalized against NC ETOH treated 
condition. All ChIP qPCR experiments were repeated three times. (C) Box plot 
showing the FAIRE qPCR experiments after NFIC or FoxA1 silencing on NFIC 
unique ARBS. All relative FAIRE signal enrichments have been normalized 
against NC ETOH treated condition. (D) Box plot showing the FAIRE qPCR 
experiments after NFIC or FoxA1 silencing on FoxA1 unique ARBS. All relative 
FAIRE signal enrichments have been normalized against NC ETOH treated 






It is not to our surprise to find out patterns of NFIC and FoxA1 functioning as 
pioneering factor to AR respectively at those ARBS not co-occupied by both 
factors. Previous studies have indicated the role of FoxA1 to modulate chromatin 
accessibility and direct AR recruitment to respective ARBS it preoccupies 
(Eeckhoute et al., 2009). It is interesting to discover the role of NFIC as 
pioneering factor to AR, acting in a similar manner to FoxA1 at ARBS occupied 
by AR and NFIC only. This suggests NFIC could function independently as a 
pioneering factor to AR and gives rise to questions about what the mechanism is 
like at FoxA1 and NFIC co-bound regions.   
We summarize our above results so far, that these results indicate that NFIC and 
FoxA1 function as pioneering factor to facilitate AR recruitment to NFIC and 
FoxA1 uniquely occupied ARBS respectively in an independent manner.  And 
whether there is collaboration between NFIC and FoxA1 in mediating AR 










Figure 3.11 Schematic diagram illustrating how NFIC and FoxA1 coordinate 
AR transcriptional activity at distinct classes of ARBS. 
 (A) At NFIC unique ARBS, NFIC plays the role of AR pioneering factor and 
facilitate the AR recruitment. (B) At FoxA1 unique ARBS, FoxA1 plays the role 






3.4 NFIC has multiple mechanisms in distinct ARBS defined by FoxA1 
3.4.1 FoxA1 regulated a large number of genes also regulated by NFIC  
To obtain a global view of the coregulatory functions of NFIC and FoxA1 on AR 
transcription, we next performed genome wide microarray expression profiling in 
LNCaP cell line after depleting FoxA1. FoxA1 depletion was performed in 
accordance to NFIC knockdown conditions. Cells were transfected with negative 
control siRNA as well as siRNA against FoxA1 for 72 hours, followed by 
treatment with or without DHT for 12 hours after the total RNA have been 
collected. 
We adopted 1.3 fold changes for the DHT responsiveness and 1.3 fold changes as 
threshold for FoxA1 dependency. As a result, we observed a striking difference 
between the expression patterns of FoxA1 regulated genes before and after FoxA1 
depletion. 
Comparing the NFIC regulated genes with the FoxA1 regulated genes, we found 
that around 42% of NFIC regulated genes are also regulated by FoxA1 and the 
rest 58% of genes are regulated by NFIC without interference by FoxA1. 
Therefore these datasets provided candidates for the subsequent analysis of the 













Figure 3.12 NFIC regulate a substantial amount of FoxA1 regulated genes 
(A) Microarray gene expression profiling was performed on LNCaP cells 
transfected with control or FoxA1 siRNA and stimulated with ETOH as vehicle or 
DHT for 12 hours. The heatmap represents all DHT-regulated genes and fold 
change in expression is indicated below. All results represent the average of 3 
independent experiments ±S.E.M. (B) Vann Diagram showing the overlap 
between NFIC regulated genes and FoxA1 regulated genes obtained from 







3.4.1 NFIC plays the role of pioneering factor instead of FoxA1 at FoxA1 
independent ARBS 
Next we sought to explore the regulatory roles of NFIC and FoxA1 on NFIC and 
FoxA1 co-localized ARBS.  From the expression microarray and the ChIP-Seq 
datasets of AR, NFIC and FoxA1, we selected several androgen responsive and 
NFIC regulated genes associated with ARBS occupied by both NFIC and FoxA1. 
By performing the expression microarray after FoxA1 depletion under similar 
condition to NFIC knockdown microarray, we compared the gene list to the NFIC 
regulated gene sets , and found out that some of the NFIC regulated genes are also 
regulated by FoxA1, while another substantial group of NFIC regulated genes are 
independent on FoxA1 depletion.  
Based on this, we further classified the ARBS associated with these genes into 
FoxA1 independent and pioneered regions. And this is consistent with recent 
studies that revealed distinct AR binding programs defined by FoxA1 in LNCaP 
prostate cancer cell line. FoxA1 depletion elicits extensive redistribution of AR 
binding events and this is correlated with changes in androgen-dependent gene 
expressions (Sahu et al., 2011; Wang et al., 2011). 
Although AR, NFIC and FoxA1 co-occupy around a few well characterized AR 
model genes such as PSA, KLK2 and TMPRSS2 (Figure 4A), none require 
FoxA1 for gene activation (Figure 4B), but were found to be regulated by NFIC 
(Figure 2D). Additionally, depletion of FoxA1 did not affect AR recruitment to 
ARBS associated with these genes (Figure 4C), suggesting NFIC plays a more 
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important role as pioneering factor to AR at these AR model gene associated 
ARBS. Although they were occupied by FoxA1 as well, FoxA1 does not appear 
to play any regulatory role. Next we carried out knock down of NFIC or FoxA1 
and checked the subsequent binding of either factor, but  both seem not to be 
required for the recruitment of the other (Figure 4D and 4E), suggesting NFIC and 



























Figure 3.13 NFIC plays pioneering factor of AR at AR model genes instead of 
FoxA1 
(A) Effect of FoxA1 silencing on PSA, TMPRSS2, KLK2 expression levels. 
LNCaP cells were maintained in hormone depleted medium followed by 
transfection with either control negative control siRNA or siRNA targeting 
against FoxA1 prior to stimulation with or without 10 nM of DHT for 12 hr. Total 
RNA was isolated and amplified with real-time RT-qPCR primers for PSA, 
TMPRSS2 and KLK2. mRNA expression levels were normalized against 
GAPDH. (B) ChIP-qPCR of AR occupancy after FoxA1 silencing at the PSA, 
KLK2, and TMPRSS2. (C) ChIP-qPCR of FoxA1 occupancy after NFIC 
silencing at the PSA, KLK2, and TMPRSS2. (D) ChIP-qPCR of NFIC occupancy 
after FoxA1 silencing at the PSA, KLK2, and TMPRSS2. All results represent the 





To provide support to our hypothesis on the mechanism of NFIC in mediating AR 
transcription alone at FoxA1 independent loci,  additional FoxA1 independent 
ARBS have been revealed from gene expression profiling and ChIP assay 
validation, namely, AADAT, MBOAT2, NDRG1, SGK3 and SEC24D. As can be 
observed from Figure 3.14, these genes were all NFIC regulated genes but 
independent of FoxA1 regulation with patterns pretty similar to the few AR model 
genes. Depletion of neither NFIC nor FoxA1 affected the occupancy of one 
another on these loci, indicating NFIC is pioneering factor of AR where FoxA1 
































Figure 3.14 NFIC pioneers AR mediated transcription instead of FoxA1 at 
FoxA1 independent/occupied ARBS  
(A) Effect of NFIC silencing on AADAT, MBOAT2, NDRG1, SGK3, and 
SEC24D mRNA expression levels. LNCaP cells were maintained in hormone 
depleted medium followed by transfection with either control negative control 
siRNA or siRNA targeting against NFIC prior to stimulation with or without 10 
nM of DHT for 12 hr. Total RNA was isolated and amplified with real-time RT-
qPCR primers for AADAT, MBOAT2, NDRG1, SGK3, and SEC24D. mRNA 
expression levels were normalized against GAPDH. (B) Effect of FoxA1 
silencing on AADAT, MBOAT2, NDRG1, SGK3, SEC24D expression levels.  (C) 
ChIP-qPCR of AR occupancy after NFIC silencing at the AADAT, MBOAT2, 
NDRG1, SGK3, and SEC24D.  (D) ChIP-qPCR of AR occupancy after FoxA1 
silencing at the AADAT, MBOAT2, NDRG1, SGK3, and SEC24D. (E) ChIP-
qPCR of FoxA1 occupancy after NFIC silencing at the AADAT, MBOAT2, 
NDRG1, SGK3, and SEC24D. (F) ChIP-qPCR of NFIC occupancy after FoxA1 
silencing at the AADAT, MBOAT2, NDRG1, SGK3, and SEC24D. All results 






In order to find out the role of NFIC and FoxA1 in modulating chromatin 
accessibility at FoxA1 independent co-occupied ARBS, FAIRE qPCR 
experiments were subsequently performed after silencing of NFIC and FoxA1 
respectively. FAIRE qPCR provided further evidence for the effect of both factors 
to AR recruitment and transcription, that NFIC plays a more important role than 
FoxA1 for opening the chromatin structures at FoxA1 independent/NFIC 
pioneered ARBS (Figure 6A). 
Above results suggest that the co-presence of several transcription factors does 
not necessarily indicate all are functioning in transcriptional regulation. AR 
transcription is mainly mediated by key regulators including NFIC in the context 
of FoxA1 independent ARBS. The schematic diagram depicting the mechanism 
of NFIC and FoxA1 in mediating AR transcription at FoxA1 independent ARBS 
is shown in Figure 3.15, that FoxA1 and NFIC are both present and co-occupy the 
chromatin prior to DHT stimulation. However, FoxA1 only binds to chromatin as 
a redundant factor without contributing to the remodeling of chromatin state. 
NFIC instead modulates chromatin accessibility that subsequently facilitates AR 
recruitment to the ARBS after DHT stimulation, and enhances AR dependent 
















Figure 3.15 NFIC modulates chromatin accessibility to facilitate AR 
mediated transcription instead of FoxA1 at FoxA1 independent/occupied 
ARBS  
 (A) Box plot showing the FAIRE qPCR experiments after NFIC or FoxA1 
silencing on FoxA1 occupied/independent ARBS. All FAIRE signal enrichments 
are normalized against NC ETOH treated conditions. (B) Schematic diagram 
illustrating how NFIC and FoxA1 coordinate AR transcriptional activity at 
NFIC/FoxA1 overlapping ARBS where AR recruitment and gene regulation is 







3.4.2 NFIC collaborate with FoxA1 to contribute to AR transcription at FoxA1 
pioneered ARBS 
Besides the set of genes regulated by NFIC alone without interference by FoxA1, 
we also would like to examine the mechanism of NFIC and FoxA1 coregulation 
at NFIC and FoxA1 co-pioneered regions. Since microarray analysis of NFIC 
regulated gene set and FoxA1 regulated gene set suggest 42% of NFIC regulated 
genes are also regulated by FoxA1, and there’s a striking enrichment of Forkhead 
motif in the NFIC and AR binding peaks, we propose there’s a collaborative 
mechanism of NFIC and FoxA1 in regulating a subset of AR target genes. 
Genes such as SASH1, LRIG1, AFF3, SLC2A12, PNMA1, SEPP1 and DEGS1 
are found to be FoxA1 and NFIC co-pioneered genes selected from the gene 
expression profiling dataset and ChIP validation. The cis-regulatory elements of 
these genes were found to be co-localized by AR, NFIC and FoxA1 and co-
regulated by NFIC and FoxA1. By knocking down NFIC and FoxA1 respectively, 
we are able to observe a drop in expression of these genes to different extents 
(Figure 5A, 5B). In accordance to the expression profiling of these gene 
candidates, we subsequently performed AR ChIP under the condition of NFIC 
and FoxA1 depletion respectively. And it has been found that recruitment of AR 
is reduced after depleting either NFIC or FoxA1 (Figure 5C, 5D).  
Interestingly, the mutual dependency between NFIC and FoxA1 for the 
recruitment of each other exhibits distinct patterns for different genes. Based on 
the mutual knockdown ChIP, genes such as SASH1, AFF3, SLC2A12 and 
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PNMA1 shows that FoxA1 depletion resulted in a significant decrease of NFIC 
occupancy, while knocking down NFIC did not affect the binding of FoxA1, 
indicating at these loci FoxA1 acts upstream of NFIC and is required for NFIC to 
bind to chromatin, and both collaborate as AR pioneering factor (Figure 5E and 
5F). However, NFIC and FoxA1 did not show mutual dependency near LRIG1, 
SEPP1 and DEGS1 (Figure 5F), and it’s likely that both factors function 


























Figure 3.16 NFIC and FoxA1 collaborate at several FoxA1/NFIC co-
pioneered genes  
(A) Effect of NFIC silencing on SASH1, LRIG1, AFF3, SLC2A12, PNMA1, 
SEPP1, and DEGS1 mRNA expression levels. LNCaP cells were maintained in 
hormone depleted medium followed by transfection with either control negative 
control siRNA or siRNA targeting against NFIC prior to stimulation with or 
without 10 nM of DHT for 12 hr. Total RNA was isolated and amplified with 
real-time RT-qPCR primers for SASH1, LRIG1, AFF3, SLC2A12, PNMA1, 
SEPP1, and DEGS1. mRNA expression levels were normalized against GAPDH. 
(B) Effect of FoxA1 silencing on SASH1, LRIG1, AFF3, SLC2A12, PNMA1, 
SEPP1, and DEGS1 expression levels.  (C) ChIP-qPCR of AR occupancy after 
NFIC and FoxA1 silencing at the SASH1, LRIG1, AFF3, SLC2A12, PNMA1, 
SEPP1, and DEGS1.  (D) ChIP-qPCR of FoxA1 occupancy after NFIC silencing 
at the SASH1, LRIG1, AFF3, SLC2A12, PNMA1, SEPP1, and DEGS1. (E) 
ChIP-qPCR of NFIC occupancy after FoxA1 silencing at the SASH1, LRIG1, 
AFF3, SLC2A12, PNMA1, SEPP1, and DEGS1. All results represent the mean ± 





Similar patterns can be observed on additional FoxA1/NFIC dependent ARBS 
such as LPAR3, PEX10, CORO2A, DNM1L and THRAP3. These additional 
candidates are also selected from the genome wide microarray gene expression 
profiling of FoxA1 and NFIC respectively. Among these candidates, LPAR3 has 
been reported as pioneered by FoxA1 in previous studies (Wang et al., 2011).  
Expression of these genes are regulated by both NFIC and FoxA1, and the 
decrease in mRNA expression after silencing either factor is correlated to a 
compromise in the AR recruitment after either factor is knocked-down in the 
ChIP q-PCR experiments. Mutual knockdown ChIP also shows distinct patterns 
in these set of candidates and further classifies them into two subtypes. PEX10, 
LPAR3 and CORO2A shows a consistent decrease in NFIC recruitment after 
FoxA1 silencing, suggest FoxA1 act upstream of NFIC at this class of ARBS, 
while this pattern is not observed at DNM1L and THRAP3. Silencing NFIC, 
however, has no appreciable effect on FoxA1 recruitment, suggesting FoxA1 
selectively act as AR pioneering factor upstream of NFIC regulation, and both 






























Figure 3.17 NFIC and FoxA1 collaborate at additional FoxA1/NFIC co-
pioneered genes  
 (A) Effect of NFIC silencing on LPAR3, PEX10, CORO2A, DNM1L and 
THRAP3 mRNA expression levels. LNCaP cells were maintained in hormone 
depleted medium followed by transfection with either control negative control 
siRNA or siRNA targeting against NFIC prior to stimulation with or without 10 
nM of DHT for 12 hr.  Total RNA was isolated and amplified with real-time RT-
qPCR primers for LPAR3, PEX10, CORO2A, DNM1L and THRAP3. mRNA 
expression levels were normalized against GAPDH. (B) Effect of FoxA1 
silencing on LPAR3, PEX10, CORO2A, DNM1L and THRAP3 expression levels.  
(C) ChIP-qPCR of AR occupancy after NFIC silencing at the LPAR3, PEX10, 
CORO2A, DNM1L and THRAP3.  (D) ChIP-qPCR of AR occupancy after 
FoxA1 silencing at the LPAR3, PEX10, CORO2A, DNM1L and THRAP3. (E) 
ChIP-qPCR of FoxA1 occupancy after NFIC silencing at the LPAR3, PEX10, 
CORO2A, DNM1L and THRAP3. (F) ChIP-qPCR of NFIC occupancy after 
FoxA1 silencing at the LPAR3, PEX10, CORO2A, DNM1L and THRAP3. All 





We would like to examine whether both FoxA1 and NFIC contribute to the 
remodeling of chromatin accessibility as well and subsequently performed FAIRE 
experiments. As expected, FAIRE qPCR results suggest that both NFIC and 
FoxA1 contribute to modulating chromatin accessibility at FoxA1/NFIC 
pioneered ARBS (Figure 6A). Above results indicated a hierarchy of the AR 
transcriptional regulation by NFIC and FoxA1, found at the NFIC and FoxA1 co-
pioneered ARBS. 
The schematic diagram illustrating the role of NFIC and FoxA1 at NFIC/FoxA1 
co-pioneered regions are shown in Figure 3.18. Both NFIC and FoxA1 contribute 
to the modulation of chromatin accessibility in this type of ARBS. The chromatin 
remodeling function of NFIC and FoxA1 facilitates subsequent AR recruitment 
after DHT stimulation, therefore promotes the NFIC/FoxA1 co-pioneered genes 
such as PEX10, LPAR3, AFF3, SASH1, PNMA1 and so on.  
Taken together, the interplay between NFIC and FoxA1 has multiple mechanisms 














Figure 3.18 Both NFIC and FoxA1 modulate chromatin accessibility and 
contribute to pioneering AR mediated transcription at FoxA1/NFIC co-
pioneered regions 
(A) Box plot showing the FAIRE qPCR experiments after NFIC or FoxA1 
silencing on FoxA1 occupied/dependent ARBS. All FAIRE signal enrichments 
are normalized against NC ETOH treated conditions. (B) Schematic diagram 
illustrating how NFIC and FoxA1 coordinate AR transcriptional activity at 
NFIC/FoxA1 overlapping ARBS where AR recruitment and gene regulation is co-
pioneered by NFIC and FoxA1, there is selective collaboration between NFIC and 








AR has been shown to play a critical role in prostate development and 
carcinogenesis, and it functions in both androgen-dependent and hormone-
refractory prostate cancer (Takayama et al., 2007; Wang et al., 2007). AR-
mediated transcription in prostate cancer involves the recruitment of the AR 
together with general transcriptional machinery, collaborative factors, 
coactivators, and corepressors in coordinated temporal and spatial fashion (Beato 
and Sanchez-Pacheco, 1996; Heinlein and Chang, 2002; Heemers and Tindall, 
2007; Chng et al., 2012). By analyzing the AR occupied region sequences 
coupled with gene expression profiling, previous studies have identified a 
network of AR  transcriptional collaborative factors such as FoxA1, CEBPβ, Oct1 
and GATA2 (Wang et al., 2007; Jia et al., 2008). Pioneering factors is an 
emerging class of collaborative factors that are able to modulate condensed 
chromatin to render the binding of additional transcription factors (Jozwik and 
Carroll, 2012). Their role in hormone-dependent cancers has been implicated 
recently. For instance, AP2γ and PBX1 mediate ER transcription in ER-positive 
breast cancer (Magnani et al., 2011; Tan et al., 2011), and FoxA1 defines distinct 
classes of AR binding programs in AR-positive prostate cancer (Sahu et al., 2011; 
Wang et al., 2011). 
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In our study, chromatin immunoprecipitation coupled to massively parallel 
sequencing (ChIP-Seq) allowed us to identify the genome-wide AR binding 
cistromes in LNCaP prostate cancer cell line. And by combining molecular, 
genomic, and bioinformatic approaches, we have identified NFIC as a novel 
collaborative factor in the androgen signaling pathway that is critical for the AR 
mediated gene transcription.  
We showed that NFIC is globally recruited across the genome prior to androgen 
stimulation and mediates AR binding to the cis-regulatory elements that drive 
transcription of AR target genes, such as PSA, KLK2, and TMPRSS2. 
Interestingly, the expressions of these AR model target genes have been shown to 
be independent of FoxA1 regulation based on FoxA1 knockdown studies (Jia et 
al., 2008; Sahu et al., 2011). Silencing FoxA1 in LNCaP prostate cancer cells 
results in differentiating AR binding programs into distinct classes based on 
subsequent AR occupancy and expression profiles, and FoxA1 was found to 
function distinctively at these ARBS (Sahu et al., 2011; Wang et al., 2011). Those 
well known AR target genes, such as PSA, KLK2 and TMPRSS2, happen to be 
occupied by FoxA1, but neither their expression nor the recruitment of AR to sites 
associated with these genes are affected by FoxA1 depletion. In such cases, AR 
recruitment and chromatin structure might have been modulated by factors other 
than FoxA1, and our study suggested that NFIC might be one of the regulators at 
these FoxA1 independent ARBS. 
      Hence it intrigued us to examine the role of NFIC at the distinct ARBS 
defined by FoxA1. Surprisingly, we found that NFIC has distinct roles in 
110 
 
regulating the AR transcriptional regulation at different classes of ARBS 
classified by FoxA1 occupancy and functions. Our observation can be divided 
into the following classes. 
(1).For NFIC unique ARBS that are void of FoxA1 occupancy, NFIC serves as 
the pioneering factor to facilitate AR recruitment at these ARBS.  (2).For FoxA1 
unique ARBS not occupied by NFIC, it is FoxA1 that plays the role as AR 
pioneering factor to guide the binding of AR.  (3). For NFIC and FoxA1 co-
occupied regions, these ARBS can be further divided into FoxA1 dependent and 
independent sites. For FoxA1 independent regions, FoxA1 are found to occupy 
the ARBS but does not contribute to AR transcriptional regulation, and it is NFIC 
that plays the role of AR pioneering factor. At this class of ARBS, NFIC 
facilitates the recruitment of AR, mediates downstream target gene expression 
and contributes to the chromatin accessibility. While for FoxA1 dependent 
regions, we found NFIC selectively collaborates with FoxA1, possibly by forming 
a pioneering complex and both contributes to AR recruitment and subsequent 
regulation of AR target genes, as well as modulating chromatin openness. In this 
category, however, there are sites that exhibit no dependency between NFIC and 
FoxA1 on each other, possibly suggesting both factors can also function as AR 
pioneering factor independently at certain ARBS. 
Studies on pioneering factors have also investigated various histone marks that 
are possibly modulated by these factors in order to render better chromatin 
accessibility. For instance, Forkhead and GATA family members have been 
implicated to be able to open compacted chromatin by disrupting histone bindings 
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(Cirillo et al., 2002). FoxA1 has been predominantly found in H3K4me2 rich and 
H3K9me2 poor regions in prostate cancer cells, and it is able to modulate 
H3k4me2 in a genome wide manner and facilitate AR recruitment after androgen 
stimulation (Sahu et al., 2011). Another pioneering factor GATA3 has been 
shown to directly affect ER enhancer accessibility in breast cancer cells, and its 
depletion resulted in a global redistribution of active histone marks such as 
H3K4me1 and H3K27Ac (Theodorou et al., 2013). However, from the site 
specific histone mark ChIP assays, we did not observe a significant change in 
H3K4me1/me2 after depleting NFIC (Figure 4.1), although the chromatin 
accessibility determined by FAIRE assays shows NFIC has certain impact. This 
might be due to the possibility that NFIC modulates chromatin accessibility via 
other histone marks at these ARBS. 
Collectively, our data suggests that NFIC is one essential component of AR 
transcriptional complex, and mediates the recruitment of AR and the transcription 












Figure 4.1 NFIC have no effect on H3K4me1/2 marks 
(A) Boxplot showing the recruitment of H3K4me1 at 15 ARBS. Individual ChIP 
assays have been repeated at least three times. (B) Boxplot showing the 
recruitment of H3K4me2 at 15 ARBS. Individual ChIP assays have been repeated 




CONCLUSION, FUTURE DIRECTIONS AND PERSPECTIVES 
 
In the current study based on AR, NFIC ChIP-seq, we have identified a novel AR 
cofactor belonging to the NFI family of transcription factors. From the genomic 
analysis of the binding profile of NFIC, we further established NFIC as a novel 
pioneering factor of AR that preoccupy the chromatin prior to DHT treatment and 
facilities chromatin remodeling. Based on molecular characterization, we 
demonstrated that NFIC is required for AR recruitment and the regulation of AR 
target gene transcription. Motif analysis of the AR and NFIC co-occupied regions 
reveals that FoxA1 might come into play in the NFIC and AR regulatory network. 
From the expression profiling datasets, we selected genes differentially regulated 
by FoxA1 and NFIC, and functionally dissect the role of NFIC as a pioneering 
factor in relation to another pioneering factor, FoxA1, in mediating AR 
transcriptional regulations. We discovered that NFIC mediates AR transcriptional 
regulation at distinct classes of ARBS defined by their dependency on FoxA1, 
and at these sites NFIC and FoxA1 differentially modulates chromatin 
accessibility, thereby potentiated the role of NFIC in the prostate cancer 
development.  
In order to obtain a more comprehensive of picture of the pioneering factor role of 
NFIC in mediating AR transcription, generating a genome wide AR ChIP-seq 
library under the condition of NFIC depletion would provide important 
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information. However, due to the technical difficulty such as knockdown 
efficiency happens to be the major challenge in this study. In future study of the 
current project, it would be important to use a more efficient siRNA against NFIC 
without disturbing AR expression levels to generate the genome wide binding 
profile of AR, thus provide evidence for NFIC pioneering regulations globally. 
Based on the oncomine database that deposit available clinical transcriptome 
studies, we found that NFIC is overexpressed in many advanced prostate 
carcinoma tissues relative to primary site (Lapointe et al., 2004; Yu et al., 2004). 
This suggests that NFIC might play a role in the prostate cancer progressions. Our 
current cell model LNCaP is an androgen responsive human prostate 
adenocarcinoma cell line derived from the left supraclavicular lymph node 
metastasis. It has been well characterized and chosen to be cell model for AR 
positive prostate cancer studies based on its androgen responsiveness. However, 
in terms of invasiveness, LNCaP is not very aggressive as observed in many 
invasion assays, therefore to fully understand the role of NFIC in the progression 
of the more advanced prostate cancer, characterization of other more invasive cell 
lines might provide deeper insight. 
Studies on pioneering factors of AR in the context of prostate cancer have 
provided insight into the genome wide redistribution of the AR binding programs 
after FoxA1 depletion (Sahu et al., 2011; Wang et al., 2011). They also left gaps 
of knowledge for future studies to fill. For example, those ARBS independent of 
FoxA1 regulation include several well characterized AR model genes such as 
PSA, KLK2 and TMPRSS2, which are frequently implicated in the AR dependent 
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prostate cancer studies. If these model genes are not regulated by FoxA1, what 
factor might contribute to the pioneering of AR regulation of these genes? Our 
current study has partially filled this gap of knowledge by providing an 
interplayer NFIC that pioneers the transcription of several FoxA1 independent 
genes at ARBS co-occupied by NFIC and FoxA1. Since previous studies in 
pioneering factors have assigned certain roles of epigenetic modulation to several 
pioneer factors, our study also investigated the potential histone marks that might 
be modulated by NFIC to facilitate chromatin remodeling at those ARBS it 
pioneers, but so far we have not established a detailed epigenetic mechanism 
regulated by NFIC. More histone marks such as other active histone methylation 
and acetylation could be analyzed to understand how NFIC contributes to the AR 
transcriptional regulation in the epigenetic point of view. It would also be 
interesting to investigate the role of FoxA1 at those ARBS it occupies without 
contributing to the regulation of the target gene. 
Taken together, our studies established NFIC as a novel pioneering factor to 
regulate AR transcription and dissected the multiple mechanisms of NFIC to co-
regulate AR transcription with FoxA1 at ARBS either dependent or independent 
on FoxA1 regulation. We are currently investigating the functional role of NFIC 
in regulating prostate cancer progession, and hopefully would provide deeper 
insight and evidence for NFIC to be considered a potential attractive candidate as 
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AR/FOXA1_8_F TGC CAC CTT GTG TAT TTT TTG ATA C 
AR/FOXA1_8_R TCA CGC CAC TGT GTA CAA TAC ATA GT 
AR/FOXA1_9_F GTG TTA AGA GCT CTC ACA ATA CAA GGA 
AR/FOXA1_9_R AAT GTC CCC ATT AAA CCA ATA AGG 
AR/FOXA1_10_F GGG AAG AGA TTA GTG TTT TGA GAT GTT 
AR/FOXA1_10_R GCA AAA GCA CTG GTA ATC TCA GTA AA 
PSA enh_F TGGGACAACTTGCAAACCTG 
PSA enh_R CCAGAGTAGGTCTGTTTTCAA 
KLK2 enh_F GTTGAAAGCAGACCTACTCTGGA 
KLK2 enh_R CTGGACCATCTTTTCAAGCAT 
KLK2 prom_F GGGAATGCCTCCAGACTGAT 














































































































List of siRNA sense sequences 
siNC 1
st
 BASE Pte Ltd 
            sense 5'-rUrUrC rUrCrC rGrArA rCrGrU rGrUrC rArCrG rUTT-3' 
            antisense 5'-rArCrG rUrGrA rCrArC rGrUrU rCrGrG rArGrA rATT-3' 
siNFIC Dharmacon ON-TARGETplus SMARTpool siRNA NM_005597 
            sense 5'-GGAGCAAGCGGCACAAAUC-3'  
            sense 5'-GAACAGGACCCAACUUCUC-3'  
sense 5'-AGACAGAGAUGGACAAGUC-3'  
sense 5'-GCUCAAAGAUCUUGUCUCG-3'  
siFoxA1 Dharmacon 
            sense 5'-GAGAGAAAAAAUCAACAGC-3'  
antisense 5'-GCUGUUGAUUUUUUCUCUC-3'. 
 
